Marshall Wace LLP Buys 152,010 Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Marshall Wace LLP increased its holdings in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 61.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 399,849 shares of the company's stock after purchasing an additional 152,010 shares during the period. Marshall Wace LLP owned 0.93% of Soleno Therapeutics worth $17,973,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. TimesSquare Capital Management LLC purchased a new position in shares of Soleno Therapeutics in the fourth quarter worth $15,273,000. Vanguard Group Inc. lifted its stake in Soleno Therapeutics by 19.2% in the 4th quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock worth $84,710,000 after purchasing an additional 303,806 shares in the last quarter. Pictet Asset Management Holding SA lifted its stake in Soleno Therapeutics by 48.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 851,838 shares of the company's stock worth $38,290,000 after purchasing an additional 276,225 shares in the last quarter. Emerald Advisers LLC boosted its holdings in shares of Soleno Therapeutics by 85.4% during the 4th quarter. Emerald Advisers LLC now owns 580,919 shares of the company's stock valued at $26,112,000 after purchasing an additional 267,585 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Soleno Therapeutics by 14.5% during the fourth quarter. Wellington Management Group LLP now owns 782,265 shares of the company's stock valued at $35,163,000 after purchasing an additional 99,095 shares in the last quarter. 97.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on SLNO. Robert W. Baird increased their price target on Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Cantor Fitzgerald increased their target price on Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. HC Wainwright restated a "buy" rating and issued a $100.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Laidlaw increased their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research report on Thursday, March 27th. Finally, Lifesci Capital upgraded shares of Soleno Therapeutics to a "strong-buy" rating in a report on Tuesday, February 4th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $104.67.

Insiders Place Their Bets

In other Soleno Therapeutics news, VP Michael F. Huang sold 14,583 shares of the firm's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $69.51, for a total transaction of $1,013,664.33. Following the transaction, the vice president now owns 36,817 shares of the company's stock, valued at approximately $2,559,149.67. This trade represents a 28.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Patricia C. Hirano sold 3,782 shares of the business's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total transaction of $265,156.02. Following the completion of the sale, the insider now owns 27,036 shares of the company's stock, valued at approximately $1,895,493.96. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 942,672 shares of company stock worth $64,058,781 over the last quarter. Company insiders own 12.30% of the company's stock.

Soleno Therapeutics Stock Down 1.3 %

NASDAQ:SLNO traded down $0.97 during mid-day trading on Friday, hitting $73.26. 776,359 shares of the stock traded hands, compared to its average volume of 735,511. The stock has a market capitalization of $3.36 billion, a price-to-earnings ratio of -22.07 and a beta of -2.29. Soleno Therapeutics, Inc. has a 52 week low of $36.93 and a 52 week high of $74.50. The firm's 50 day moving average is $57.41 and its two-hundred day moving average is $52.85.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.41). As a group, research analysts predict that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.